Tesla
TSLA
Apple
AAPL
Meta Platforms
META
Intel
INTC
Microsoft
MSFT
US Stock MarketDetailed Quotes
QTTB Q32 Bio
- 2.070
- -0.010-0.48%
Close Mar 21 16:00 ET
- 2.000
- -0.070-3.38%
Post 20:01 ET
25.25MMarket Cap-0.40P/E (TTM)
2.183High2.030Low75.49KVolume2.070Open2.080Pre Close155.89KTurnover1.60%Turnover RatioLossP/E (Static)12.20MShares53.79052wk High4.45P/B9.79MFloat Cap1.80052wk Low--Dividend TTM4.73MShs Float546.837Historical High--Div YieldTTM7.34%Amplitude1.800Historical Low2.065Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Q32 Bio Stock Forum
Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Positive
Statistically significant 16% SALT score reduction vs 2% placebo at week 24 (p=0.045)
Durable response with continued improvement after treatment cessation through week 55
Clean safety profile with no Grade 3+ treatment-related adverse events
Strong patient interest with multiple requests to re-initia...
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Saturday, 8th March at 11:00 am
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) --
-- Durable, ongoing responses in multiple ...
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Friday, 28th February at 9:00 am
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) --
WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 ...
$Q32 Bio (QTTB.US)$
has options
nfa
$Q32 Bio (QTTB.US)$
$Richtech Robotics (RR.US)$
$SEALSQ Corp (LAES.US)$
$XTI Aerospace (XTIA.US)$
$MicroCloud Hologram (HOLO.US)$
$Q32 Bio (QTTB.US)$ reverse trend? get it before it's talked about, after a 50 percent gain day.... 22 percent shorts float.... they had some horrible news on december 11th. did there dip. most analysts have downgraded targets from $40-$50 down to $10-$20. which is still considerably higher than $4. looks to have consolidated around the 3-4. breaking the downward trend. I will be buying before the burst this week.... low shares low float. ... risky business is the name of the...
Worse than placebo for Eczema, ouch
Alopecia worked well, but probably people were looking for the eczema market?
No comment yet